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Epigenetic biomarkers including aberrantly methylated DNA
(amDNA) and non-coding RNA such as microRNAs (miRNAs)
and long non-coding RNAs (lncRNAs) in biological fluids repre-
sent markers with the highest potential for cancer diagnostics.
Tumor-specific amDNA is more easily and efficiently detected in
blood plasma/serum in presence of large excess of wild type
DNA compared with mutated DNA. miRNAs are much more
stable than coding mRNA and are present in blood in detectable
amounts. However still only a few cell-free DNA (cfDNA) -based
diagnostics detecting epigenetic markers have come to the
market. The main limitations of aberrantly methylated cfDNA
(am-cfDNA) markers are age- and tissue-specific DNA methyla-
tion, low concentration of tumor-specific DNA along with pres-
ence of any conceivable methylated DNA pattern in circulation
(Korshunova, 2009). Potential miRNA markers selection demands
large scale primary analysis and overcoming some analytical
complication like efficiency and uniformity of miRNA isolation
and normalization at verification step.
To overcome limitations of am-cfDNA use we utilized two
approaches:
Biased comprising selection of markers valid for tumor
tissues, elaboration of the demands for inclusion/exclusion of
cfDNA samples, development of PCR with absolute specificity
and sensitivity of 1–10 molecules per sample, increasing of
cfDNA concentration in the analytical sample. Epigenomics
GA successfully used this approach for the EpiColon test
development.
Unbiased comprising search for potential markers in cfDNA/
cfRNA using modern methods including MPS and subsequent
bioinformatics data analysis, formulation of the requirements
to analytical systems based on MPS data, development and
validation of the diagnostics.
Using first approach we selected 4 markers from 5 studied
which proposed diagnostic value for lung cancer. Analytical sen-
sitivity of methyl-specific TagMan PCR for these 4 genes and a
control gene are 2, 3, 4, 10 and 10 copies of methylated DNA in
1000-fold excess of unmethylated DNA, correspondingly.
Diagnostic sensitivity of lung cancer detection in the training
group (30 healthy, 30 lung cancer patients, training cohort) for 4
genes are 13%, 46%, 73%, 30%, specificity – 100%, 97%, 100%,
97%, respectively. Inclusion/exclusion criteria are based on a
control gene concentration in blood plasma. 2 markers in
combination provide 89%sensitivity of lung cancer diagnostics
and 97% specificity, 3 markers in combination demonstrate
sensitivity and specificity of 92% and 97%.
Unbiased approach included locus-specific MPS using MiSeq
platform of 2 aberrantly methylated genes amplified with
methyl-independent primers (barcoded individually) after bisul-
fite conversion of cfDNA isolated from blood of 18 healthy donors
(HD), 20 prostate cancer (PC) and 17 benign prostatic hyperplasia
patients (BPH). Analysis of individual methylation patterns and
their representation demonstrates that methylation of GSTP1
gene-located 4 CpG-pairs in cfDNA from healthy donors differs
compared with PC patients. Logistic regression-based model of
4 CpG-pairs methylation demonstrates 95% specificity and 100%
sensitivity of PC diagnostics.
Looking for miRNA markers 20 primary lung cancer patients
(14 – squamous cell carcinoma, 6 – adenocarcinoma) and 10
healthy donors were enrolled in the study (training cohort). Circu-
lating miRNAs were isolated by one-step phenol-free protocol
(Zaporozhchenko et al., 2015). Concentrations of 179 miRNAs
were measured in circulating miRNA pool by miRCURY LNA
microRNA PCR Serum/Plasma Panel (Exiqon Ltd, Denmark). 18
miRNAs were differentially expressed between groups of healthy
donors and patients with squamous cell carcinoma. 2 miRNAs
provide 85% and 79% diagnostic sensitivity with 100% specificity.
Verification using qRT-TaqMan PCR on a testing cohort including
75 lung cancer patients (squamous cell carcinoma and adenocar-
cinoma) and 50 healthy donors demonstrates 66% sensitivity and
89% specificity of the best selected miRNA.
In conclusion, wide scale modern methods demonstrate high
efficacy for epigenetic cfNA cancer markers development,
whereas conventional approaches based on the current experi-
ence have not yet exhausted their potential.
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This work is devoted to the actual problem of studying modern
ideas about the systemic treatment of brain tumors, in particular
on the implementation and effectiveness of modern methods of
immunomodulation in neuro-oncology. The aim is to clarify the
existence of patients with brain tumors immunosuppression,
resulting in testimony to the development and application of
methods of immunotherapy. Method of research consistent with
the goal and objectives of the study, which included a dynamic
examination of 32 operated patients with hemispheric brain glio-
mas. Cycloferon interferonogens from the group, which has
antiviral and antitumor action potential was used as an
immunomodulator us. It is of interest to determine the effective-
ness of immunomodulatory action of cycloferon in patients with
brain tumors in different phases of development of cancer. This
work represents a scientific novelty and practical significance
for solving urgent problems of neurology and neurosurgery –
the study of the cycloferon drug, has proved its effectiveness in
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